Bill Ackman’s Pershing Square Capital Management Just increased Valeant Pharmaceuticals International Inc’s Stake
11/29/2015 BY OCTASTAFF IN SEC 13G & 13D FILINGS
Bill Ackman’s Pershing Square Capital Management increased Position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX)
Pershing Square Capital Management has filled a SC 13D/A form regarding Valeant Pharmaceuticals International, Inc 88.49 +1.40 1.60%. Filing Link: 000119312515385412. Per Bill Ackman’s Pershing Square Capital Management’s filing, the filler reported increased stake in the company by 42.92 % to 34,118,551 shares. Bill Ackman’s Pershing Square Capital Management now owns 9.9% of the Health Care-company. This form was required due to trading activity on November20, 2015.
The $15.21 billion hedge fund looks more positive after such an increase of Valeant Pharmaceuticals International, Inc’s position.
The hedge fund has been active in the Health Care sector recently. In the fund’s latest 13F, it revealed several positions. This sector is 12% of Bill Ackman’s Pershing Square Capital Management’s US equities portfolio.
Why Bill Ackman’s Pershing Square Capital Management Holds Valeant Pharmaceuticals Intl Inc (NYSE:VRX)
PURPOSE OF TRANSACTION
Item4 of the Schedule 13D is hereby amended by restatingparagraphs 2 and 4, respectively, in their entirety as set forth below:
The Reporting Persons hold their stake in the Issuer forinvestment purposes. Representatives of the Reporting Persons may conduct discussions from time to time with management of the Issuer, other stockholders of the Issuer and/or other relevant parties, including other companies in the Issuer’sindustry, in each case, relating to matters that may include the strategic plans, strategy, assets, business, financial condition, operations, and capital structure of the Issuer. The Reporting Persons may engage the Issuer, other stockholders ofthe Issuer or other relevant parties in discussions that may include one or more of the other actions described in subsections (a)through (j)of Item4 of Schedule 13D.
The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including theIssuer’s financial position and strategic direction, the outcome of the discussions referenced above, actions taken by the Board of Directors of the Issuer, price levels of the securities of the Issuer, other investment opportunities availableto the Reporting Persons, the availability and cost of debt financing, conditions in the capital markets, financial considerations of the Reporting Persons and of the funds managed by the Reporting Persons, including, but not limited to, portfolioweighting, composition and taxation, and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investments in the Issuer as they deem appropriate, including purchasing additionalsecurities of the Issuer, entering into financial instruments or other agreements which increase or decrease the Reporting Persons’ economic exposure with respect to their investments in the Issuer, selling some or all of the ReportingPersons’ respective holdings in the Issuer, engaging in any hedging or similar transactions with respect to such holdings and/or otherwise changing their intention with respect to any and all matters referred to in Item4 of Schedule 13D.
13D
CUSIP No. 91911K102 Page 6
Valeant Pharmaceuticals International, Inc Hedge Funds Ownership
Latest SEC filings show 527 hedge funds and institutional investors own Valeant Pharmaceuticals International, Inc. The institutional ownership of the company in Q1 2015 is extremely high, at 83.53 % of the shares outstanding. They increased by 12199043 the total shares they hold. As of that quarter these institutional investors owned 285010345 shares. A total of 121 funds opened new positions in Valeant Pharmaceuticals International, Inc and 151 increased their holdings. There were 53 funds that closed their positions and 205 that reduced them.
75 investors have the firm in their Top 10. Some of these are: Arrow Capital Management Llc, Bloombergsen Inc., Carnick & Kubik Llc, Catalyst Capital Advisors Llc, Consulta Ltd, First Mercantile Trust Co, Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Management Corp, Iridian Asset Management Llc Ct, Levasseur Capital Partners Llc, M&R Capital Management Inc..
HEDGE-FUNDS-LIST-DATABASE-FREE American Capital Management Inc is the most positive institutional investor on Valeant Pharmaceuticals International, Inc, with ownership of 952343 shares as of Q1 2015 for 7.03% of the fund’s portfolio. Avalon Advisors Llc is another positive player owning 37274 shares of the company or 0.32% of their stocks portfolio. TX Belmont Global Advisors Inc have 0.51% of their stock portfolio invested in the stock for 2500. Further, Brave Warrior Advisors Llc disclosed it had purchased a stake worth 35.64% of the fund’s stock portfolio in the company. The CA Churchill Management Corp was also a notable investor in the firm, owning 337073 shares. Valeant Pharmaceuticals International, Inc is 2.30% of the fund’s stock portfolio.
Company Profile
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.
Form 13D is SEC filing that must be submitted within 10 days, by anyone who acquires beneficial ownership of more than 5% of any publicly traded securities. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing. These filings may be a precursor to hostile takeovers, company breakups, and other “change of control” events.
Bill Ackman’s Pershing Square Capital Management website.
Valeant Pharmaceuticals International, Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Your Email Address
Sign-Up Now (Free)
Tagged: NYSE:VRX